Lastet - Injection Etoposide - 100mg/5ml 1 Injection(s) / Injection Unknown Introduction: Lastet is used to treat different cancers of lung, and testicles. It is also sometimes used to treat some other kinds of cancer in both men and women. It can be used on its own, or sometimes given together with certain other medicines as part of combination chemotherapy. Lastet is given as slow injection into veins under the supervision of a healthcare professional and should not be self-administered. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to... Uses of Lastet: Small cell lung cancerTesticular cancer Side effects of Lastet: Anemia (low number of red blood cells)Decreased blood cells (red cells, white cells, and platelets)Decreased white blood cell countDiarrheaHair lossLiver damageLow blood plateletsNauseaRashStomatitis (Inflammation of the mouth)Vomiting How to use Lastet: Your doctor or nurse will give you this medicine. Kindly do not self administer. How Lastet works: Lastet is an anti-cancer medication. It works by suppressing the activity of an enzyme (topoisomerase II) involved in DNA multiplication of the cancer cells. This slows the growth of cancer cells and eventually kills them. Indication: Lung cancer, Testicular cancer Adult Dose: Intravenous Testicular Cancer 50-100 mg/m²/day IV on days 1-5, OR 100 mg/m²/day IV on days 1, 3, 5 Repeat q3-4week Small-Cell Lung Cancer 35 mg/m²/day IV for 4 days, OR 50 mg/m²/day IV for 5 days; repeat q3-4week Oral Small cell lung cancer Adult: Twice the IV dose, rounded to the nearest 50 mg. Renal Dose: Renal Impairment CrCl >50 mL/min: Dose adjustment not necessary CrCl 15-50 mL/min: 75% of regular dose CrCl < 15 mL/min: Not studied; consider further dose reductions Contraindication: Hypersensitivity, pregnancy, lactation. Mode of Action: Etoposide is a derivative of podophyllotoxin that inhibits DNA synthesis resulting in the arrest of the cell cycle. At low doses, it inhibits cells from entering cell cycle and at high doses, cells entering mitosis are lysed. Precaution: Skin reactions may occur with accidental exposure; renal or hepatic disease. Periodic CBCs should be done before, during and after therapy. Increased risk of etoposide-toxicity in patients with low serum albumin. Acrylic material has been shown to crack and leak when used with undiluted etoposide inj. Lactation: not known if excreted in breast milk, discontinue drug or do not nurse Side Effect: >10% Leukopenia (60-91%),Nausea and Vomiting (30-40%),Thrombocytopenia (28-41%),Alopecia (20-90%),Anorexia (13%),Diarrhea (13%),Leukopenia (60-91%),Anemia (≤33%) 1-10% Pancytopenia (7%),Stomatitis (6%),Hepatic toxicity (3%),Type 1 hypersensitivity (2%),Orthostatic hypotension (1-2%),Peripheral neuropathy (1-2%) Frequency Not Defined Malaise,Shivering,Asthenia,Fever,Mucous membrane inflammation,Hyperuricemia,Local soft tissue toxicity has been reported following extravasation; see section on IV information for extravasation management Potentially Fatal: Severe myelosuppression, characterised by leucopaenia and thrombocytopaenia. Cardiotoxicity. Anaphylaxis. Pregnancy Category Note: Pregnancy: Based on animal data and its mechanism of action, etoposide can cause fetal harm when administered to a pregnant woman; etoposide, the active moiety of etoposide phosphate is teratogenic in mice and rats advise pregnant women of potential hazard to a fetus; advise women of childbearing potential to avoid becoming pregnant Advise females of reproductive potential to use effective contraception during treatment and for 6 months after final dose In females of reproductive potential, may cause infertility and result in amenorrhea; premature menopause can occur; recovery of menses and ovulation is related to age at treatment Lactation: There is... Interaction: Synergism with other cytotoxic drugs. Caution when admin with drugs that inhibit phosphatase activity. Cyclosporin A may reduce the clearance of etoposide.